Notably, donor-derived anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has emerged as a successful salvage or preemptive strategy in B-ALL patients following allo-HSCT [1–3]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.